- AU$75.72m
- AU$56.86m
- AU$5.09m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 34.76 | ||
| Price to Tang. Book | 69.31 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 12.5 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -52.39% | ||
| Return on Equity | -177.01% | ||
| Operating Margin | -174.76% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.96 | 0.84 | 1.22 | 1.62 | 5.09 | 4.78 | 13 | 51.53% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Orthocell Limited is an Australia-based regenerative medicine company. The Company is focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Its portfolio of products includes CelGro, Striate+, Remplir, and SmrtGraft. CelGro is a collagen medical device that facilitates tissue reconstruction and healing in a variety of dental and orthopedic reconstructive applications. CelGro is manufactured using a SMRT manufacturing process to preserve the natural collagen structure. Striate+ is used for dental GBR applications. Remplir is for peripheral nerve reconstruction. SmrtGraft is for tendon repair. Its other major products are autologous cell therapy, which focuses on regenerating damaged tendon and cartilage tissue. It is engaged in the development of its tendon cell therapy in the United States. Its autologous tendon therapy is an advanced injectable cellular therapy for the treatment of chronic tendon injuries.
Directors
- Stewart Washer CHM
- Nicole Telford CFO
- Ming Hao Zheng CSO
- Paul Anderson MDR (48)
- Leslie Wise EDR
- Simon Robertson SEC
- Lars Lidgren NED (77)
- Qi Xiao Zhou NED (44)
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 21st, 2006
- Public Since
- August 12th, 2014
- No. of Shareholders
- 5,090
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 199,267,357
- Address
- Building 191 Murdoch University, PERTH, 6150
- Web
- http://www.orthocell.com.au/
- Phone
- +61 893602888
- Auditors
- PKF Perth
Upcoming Events for OCC
Similar to OCC
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
What is the Orthocell share price?
As of Today at 19:16 UTC, shares in Orthocell are trading at AU$0.38. This share price information is delayed by 15 minutes.
How has the Orthocell share price performed this year?
Shares in Orthocell last closed at AU$0.38 and the price had moved by -9.52% over the past 365 days. In terms of relative price strength the Orthocell share price has underperformed the ASX All Ordinaries Index by -15.73% over the past year.
What are the analyst and broker recommendations for Orthocell?
The overall consensus recommendation for Orthocell is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Orthocell dividend yield?
Orthocell does not currently pay a dividend.
Does Orthocell pay a dividend?
Orthocell does not currently pay a dividend.
When does Orthocell next pay dividends?
Orthocell does not currently pay a dividend.
How do I buy Orthocell shares?
To buy shares in Orthocell you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Orthocell?
As of the previous close price of AU$0.38, shares in Orthocell had a market capitalisation of AU$75.72m.
Where are Orthocell shares listed?
Here are the trading details for Orthocell:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: OCC
What kind of share is Orthocell?
Based on an overall assessment of its quality, value and momentum Orthocell is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Orthocell share price forecast for 2024?
The analyst consensus target price for shares in Orthocell is AU$0.55. That is 44.74% above the last closing price of AU$0.38.
Analysts covering Orthocell currently have a consensus Earnings Per Share (EPS) forecast of -AU$0.05 for the next financial year.
What is the trend in the Orthocell share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Orthocell. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -4.35%.
As of the last closing price of AU$0.38, shares in Orthocell were trading -1.32% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Orthocell PE Ratio?
The Orthocell PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.38.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Orthocell?
Orthocell's management team is headed by:
- Stewart Washer - CHM
- Nicole Telford - CFO
- Ming Hao Zheng - CSO
- Paul Anderson - MDR
- Leslie Wise - EDR
- Simon Robertson - SEC
- Lars Lidgren - NED
- Qi Xiao Zhou - NED